Recent Posts

Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse

Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination.


Read more: https://www.roswellpark.org/newsroom/202211-pediatric-multicenter-study-shows-targeted-therapy-high-risk-hodgkin-lymphoma

Tags:

Archive
Search By Tags